We're crowdfunding! Own a part of our business. Capital at Risk.
View our pitch

Stablepharma Spain R&D Centre of Excellence (CoE)

Stablepharma achieved an important milestone with Td-StablevaX™ in collaboration with our strategic partner BB–NCIPD Ltd (Bul Bio) having successfully demonstrated accelerated stability for up to 10 months at +45ºC.

Click here to see our partners


Our Science Team are based at Stablepharma’s R&D Centre of Excellence (CoE) in Qube Technology Park, 20 miles from Madrid International Airport. Dr Arcadio Garcia de Castro, Chief Scientific Officer is supported by Juana de la Torres, Senior R&D Manager and Daniela Briceño Garcia, Senior R&D Technician.

The specialist team in Madrid continue their work validating the high-temperature stability of vaccines for prolonged periods of time without loss of potency. The StablevaX™ is a novel technology platform designed to dramatically enhance the thermo-stability of existing and new vaccines. It has shown strong in-vitro and in-vivo data with Tetadif (Td) and COVID mRNA. To date, the R&D CoE have identified over 60 vaccines suitable for StablevaX™.

The Science Team in Spain work closely with Stablepharma’s partners: EU Manufacturer BB-NCIPD Ltd (Bul Bio), the University of StrathclydeUniversity Hospital Southampton and University Hospital La Paz in Madrid, forging the way to making fridge-free vaccines a reality.

Qube Technology Park offers 10.000 m2 dedicated laboratories and a Business Center, housing over 40 technology and biotech companies and providing services for Animal Toxicology, Formulation Services, Lyophilisation and Quality Control.


“The technology is proven, the company continues to hit its development milestones and Stablepharma has outlined a path to both humanitarian and commercial success, which is a compelling investment story and one that I and my fellow investors strongly support”.

Will Iselin, Stablepharma Investor

Get in touch to receive further information on Stablepharma